We successfully constructed a novel nanosystem, namely, AR-NADR, which contained A54-modified RBC membrane vesicles as the shell and an NLS modified Ag-MOF loaded with DDP and NOR1 shRNA as the core for the treatment of cisplatin resistance in HCC. This evidence concerns the gene OSCP1 and hepatocellular carcinoma.